Navigation Links
Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment-Naive Hepatitis C Patients Presented At EASL
Date:4/26/2008

MILAN, Italy, April 26 /PRNewswire/ -- Schering-Plough Corporation (NYSE: SGP) today reported that results from a planned interim analysis of an ongoing Phase II study of boceprevir, its investigational oral hepatitis C protease inhibitor, in 595 treatment-naive patients with chronic hepatitis C virus (HCV) genotype 1 were presented at the 43rd Annual Meeting of the European Association for the Study of the Liver (EASL). The ongoing study evaluates boceprevir in 28-week and 48-week treatment regimens.

In a 28-week treatment regimen in which patients received 4 weeks of PEGINTRON(TM) (peginterferon alfa-2b) and REBETOL(R) (ribavirin, USP) prior to the addition of boceprevir (800 mg TID), the rate of sustained virological response at 12 weeks after the end of treatment (SVR 12) was 57 percent (ITT).(1-3) Importantly, this treatment regimen provided an indication of early predictability of response, with patients who had undetectable virus (HCV-RNA) in plasma after 4 weeks of boceprevir treatment achieving an SVR 12 rate of 86 percent.

"These interim results are very encouraging, especially given the response seen with a shorter course of therapy in a difficult-to-treat patient population," said principal investigator Paul Kwo, M.D., associate professor of medicine and medical director, liver transplantation, Department of Medicine, Division of Gastroenterology/Hepatology, Indiana University School of Medicine, Indianapolis, who presented the data. "Boceprevir has been well tolerated by patients in this study, including in the longer duration treatment arms, and we look forward to further results from this ongoing study."

Overall, 77 percent of the 595 patients in the study were enrolled in the United States. African-Amer
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Interim Analysis of Phase I/II Study of Rexin-G Confirms Efficacy With No Dose Limiting Toxicity in Metastatic Pancreatic Cancer
2. Medarex Reports Interim Data from Ongoing Ipilimumab Combination Phase 1 Studies in Prostate Cancer at American Association for Cancer Research Meeting
3. Nventa Announces Positive Interim Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial
4. NanoBio Corporation Completes Interim Analysis of Phase 2 Clinical Trial in Onychomycosis
5. Independent Data Safety Monitoring Board Recommends Continuation of Sangarts Pivotal Phase III Trials of Hemospan(R) Following Second Interim Review
6. Sunesis Pharmaceuticals Reports Positive Interim Data for SNS-595 Single-Agent Activity in Platinum-Resistant Ovarian Cancer
7. NanoBio Corporation Presents Preclinical and Interim Clinical Data on Topical Treatments for Herpes Labialis and Onychomycosis at AAD 2008
8. Interim Analysis Supports Continuation of Cell Genesys VITAL-1 Phase 3 Clinical Trial of GVAX Immunotherapy for Prostate Cancer
9. Interim Safety Analysis Supports Continuation of Allos Therapeutics Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-cell Lymphoma
10. Novavax Announces Favorable Interim Results from Human Clinical Trial for Its Pandemic Influenza Vaccine Program
11. Grantees of the Avon Foundation Breast Cancer Prevention Research Initiative Gather in Houston to Report Interim Findings
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... Calif. , Aug. 27, 2014  AcelRx Pharmaceuticals, ... company focused on the development and commercialization of innovative ... today announced that senior management will be participating at ... at the Morgan Stanley Global Healthcare Conference.  Details of ... Healthcare One on One Conference Date: Wednesday September 3 ...
(Date:8/26/2014)... Intelomed is pleased to announce that ... as the Vice President of Clinical Affairs. With over ... device industry, Kay,s experience in taking medical technology and ... to global expansion, is a valuable addition to the ... on our team, and I am confident her focused ...
(Date:8/26/2014)... NEW YORK , Aug. 26, 2014 ... market research report is available in its ... Market Outlook to 2020 ... & Gastroscopes Market Outlook to 2020 ... & Gastroscopes Market Outlook to 2020", provides ...
Breaking Medicine Technology:AcelRx Pharmaceuticals to Participate in Two Upcoming Investor Events 2AcelRx Pharmaceuticals to Participate in Two Upcoming Investor Events 3Mary Kay Deck joins Intelomed as Vice President of Clinical Affairs 2Japan Esophagoscopes & Gastroscopes Market Outlook to 2020 2Japan Esophagoscopes & Gastroscopes Market Outlook to 2020 3Japan Esophagoscopes & Gastroscopes Market Outlook to 2020 4Japan Esophagoscopes & Gastroscopes Market Outlook to 2020 5
... March 1, 2011 Heska Corporation (Nasdaq: ... and specialty products to veterinarians, today announced the addition ... in-clinic blood analyzers. (Logo:   http://photos.prnewswire.com/prnh/20000622/HESKALOGO ) ... analyzer is used to measure lactate, and is ideal ...
... successful contract packaging and re-packaging companies in the ... new, single-source industry leader called Aphena Pharma ... corporation based on a strategic alliance between Celeste ... Packaging; all long-term specialized leaders in the contract ...
Cached Medicine Technology:Heska Introduces New Lactate Meter Analyzer 2Merger of Four Pharmaceutical Companies Announced 2
(Date:8/27/2014)... (PRWEB) August 27, 2014 The world ... transformation as was revealed in a survey conducted recently ... not just surprising but astonishing as well, and for ... online interviewed existing members on the 10yeargap website and ... to Kaly, 10yeargap marketing department manager," there are more ...
(Date:8/27/2014)... August 27, 2014 AvePoint, ... and compliance software solutions for next-generation social collaboration ... magazine’s Inc. 500|5000, an exclusive ranking of the ... year. AvePoint joins brands such as Alex and ... edition. , This underscores continued growth and ...
(Date:8/27/2014)... 27, 2014 Discover Leadership Training is ... corporate transformation through their comprehensive leadership programs. As the ... unparalleled experience in the realm of outcome-focused and benefit-driven ... in a new webinar series titled, “A Women’s Guide ... first of this two part webinar is titled, “My ...
(Date:8/27/2014)... is one of the most loved online bamboo product suppliers; ... now. Recently, it has announced its new selection of ... strives to offer one-stop shopping solutions for people who want ... it is providing big discounts for all the brand new ... a discounted price (up to 30% off) before the deadline ...
(Date:8/27/2014)... Overcoming a turbulent past which branded KC ... The Women’s Radio Network, WRNW1, has recently signed a multi-million ... dedication to the WRNW1 family. KC states, “it is such ... positive atmosphere.” After KC Armstrong publicly announced his appreciation to ... Stern show, “Howard 100 News,” have decided to pay it ...
Breaking Medicine News(10 mins):Health News:Survey Reveals Younger Women Dating Older Men 2Health News:Survey Reveals Younger Women Dating Older Men 3Health News:Inc. Magazine Names AvePoint to the Inc. 500|5000 List of Fastest Growing American Companies for the Fifth Consecutive Year 2Health News:Inc. Magazine Names AvePoint to the Inc. 500|5000 List of Fastest Growing American Companies for the Fifth Consecutive Year 3Health News:Barb Moses, Vice President of Discover Leadership Training, Announces New Webinar Titled, “A Women’s Guide to Making Her Life Story a Bestseller” 2Health News:Brand New Bamboo Plywoods Now Offered At BambooIndustry.com 2Health News:The Women's Radio Network, WRNW1, Signs KC Armstrong to a Multi-Million Dollar Contract 2
... New ... Health Care Gaps Around the World , ... Westport, Conn. (Vocus) -- To address the global shortfall of 4.3 million health care workers needed ... care workers, Save the Children says in its new State of the World,s Mothers 2010 ...
... trend, study finds , TUESDAY, May 4 (HealthDay News) -- ... the United States having an abortion increased nearly 60 percent, ... , According to the report released May 4 by the ... , The proportion of women in the overall U.S. ...
... now attempting to reveal the factors that play a key role ... shows that a physically active lifestyle during adolescence can reduce the ... becoming overweight or obese. Among the genes correlated to ... genes responsible for the accumulation of fat in humans. "Each copy ...
... ... preserves the Company,s connection to its reputation as America’s leading debt resolution provider while ... ... Solutions, a premier tax debt resolution provider for individuals and businesses across America, is ...
... ... Hospital Association’s (MHA) Quality Indicator Project® has signed an agreement with ... solution with 3M™ ClinTrac™ Quality Manager Software. The joint solution ... analytical tools, and comparative reports in an integrated system, allowing hospitals ...
... A study by researchers at Columbia University,s Mailman School ... themselves in select genes, altering their functions and leading ... ,"Our findings suggest a new biological model of ... traumatic event, changes a person,s stress response and leads ...
Cached Medicine News:Health News:For a Mother's Day Gift with Lasting Appeal, Invest in Women Health Workers, Says Save the Children 2Health News:For a Mother's Day Gift with Lasting Appeal, Invest in Women Health Workers, Says Save the Children 3Health News:For a Mother's Day Gift with Lasting Appeal, Invest in Women Health Workers, Says Save the Children 4Health News:Abortion Rates Rising Among the Poor 2Health News:Physical activity reduces the effect of the obesity gene in adolescents 2Health News:Nationwide Tax Solutions Rebrands Itself as Tax Strategies 2Health News:3M and Maryland Hospital Association's Quality Indicator Project Partner to Deliver Comprehensive Quality Solution 2Health News:3M and Maryland Hospital Association's Quality Indicator Project Partner to Deliver Comprehensive Quality Solution 3Health News:Trauma-induced changes to genes may lead to PTSD 2
... The Bio-Optics LSM-12000 is a new ... powerful new tool in anterior segment diagnostics ... easy to operate, easy to maintain, and ... is the only High Magnification Slit-Lamp Biomicroscope ...
70 discs to investigate acquired color deficiency. Quantifies neutral zone characteristics of dyschromatopsia and evaluates the relative luminance....
... a rapid field or laboratory test for the ... simple, two-step test provides results in 10 minutes, ... , ,Intended use: The NOW® Hepatitis B sAg/eAg ... the detection of Hepatitis B surface antigen (HBsAg) ...
... the newest technology available in acrylic lens ... exceptional material and design properties to achieve ... , Unique foldable hydrophobic acrylic material ... biostable , High index of refraction ...
Medicine Products: